Characterisation and intracellular labelling of mesenchymal stromal cells derived from synovial fluid of horses and sheep.
Authors: Burk J, Glauche S M, Brehm W, Crovace A, Francioso E, Hillmann A, Schubert S, Lacitignola L
Journal: Veterinary journal (London, England : 1997)
Summary
Mesenchymal stromal cells (MSCs) harvested from synovial fluid represent a potentially valuable therapeutic resource for joint pathology, yet their characterisation in equine and ovine patients remained incomplete prior to this investigation. Burk and colleagues isolated SF-derived MSCs from healthy and osteoarthritic horse joints and healthy sheep synovial fluid and bone marrow, then systematically evaluated their proliferative capacity, multipotent differentiation capacity across three lineages (osteogenic, chondrogenic, adipogenic), and surface marker expression (CD73, CD90, CD105), whilst simultaneously assessing quantum dot labelling efficiency at concentrations of 2–10 nmol/L. Both species' MSCs demonstrated robust trilineage potential and appropriate marker expression; notably, equine cells favoured adipogenic differentiation whilst ovine SF-MSCs showed superior chondrogenic capacity—a distinction potentially relevant when selecting cell sources for specific joint lesions. Quantum dot labelling proved highly efficient (>98% at 10 nmol/L, >95% at 2 nmol/L immediately post-labelling), though signal persistence declined over seven days in culture, with higher concentrations retaining detectability longer. For practitioners considering MSC-based therapies or experimental studies, these findings provide a practical foundation for species selection based on desired differentiation outcomes and establish quantum dot labelling as a feasible tracking method for monitoring cell behaviour in vivo, particularly valuable for validating cell survival and distribution in treated joints.
Read the full abstract on PubMed
Practical Takeaways
- •SF-derived MSCs from horses and sheep can be reliably isolated and characterized for potential joint disease therapies, with quantum dot labelling enabling effective cell tracking in research and clinical applications
- •Species-specific differentiation patterns should be considered when selecting MSC sources for particular therapeutic goals—equine cells favor adipogenesis while ovine cells favor chondrogenesis
- •Standardized labelling protocols using quantum dots at 2-10 nmol/L provide efficient, trackable cell preparations for evaluating MSC behavior in joint environments
Key Findings
- •Quantum dot labelling of ovine SF-MSCs was highly efficient, achieving >98% positive cells at 10 nmol/L and >95% at 2 nmol/L
- •All equine and ovine MSCs from synovial fluid and bone marrow demonstrated trilineage differentiation potential with species-specific differences: adipogenesis more pronounced in equine samples, chondrogenesis most pronounced in ovine SF-MSCs
- •CD73, CD90 and CD105 were expressed at mRNA level in both equine and ovine MSCs, confirming mesenchymal stromal cell phenotype
- •Quantum dot labelling persisted over 7 days of culture with greater persistence at higher labelling concentration, enabling cell tracking for therapeutic applications